Dapagliflozin and Metformin HCl Extended Release Tablets 10 mg/1000 mg,xigduo XR 10 mg/1000 mg
Sponsors
Sun Pharmaceutical Industries Ltd.
Conditions
Healthy
Bioequivalence study
Dapagliflozin Pharmacokinetics
Metformin Pharmacokinetics
Phase 1
A Bioequivalence Study of Two Fixed-dose Combination of 10 mg Dapagliflozin and 1000 mg Metformin Hydrochloride Extended Release Tablets, xigduo XR 10 mg/1000 mg and Dapagliflozin and Metformin HCl Extended Release Tablets 10 mg/1000 mg, in Healthy Thai Subjects under Fasting Conditions
Active, not recruitingTCTR20250228004
Start: 2025-09-29Target: 60Updated: 2026-08-03
A Bioequivalence Study of Two Fixed-dose Combination of 10 mg Dapagliflozin and 1000 mg Metformin Hydrochloride Extended Release Tablets, xigduo XR 10 mg/1000 mg and Dapagliflozin and Metformin HCl Extended Release Tablets 10 mg/1000 mg, in Healthy Thai Subjects under Fed Conditions
Active, not recruitingTCTR20250302010
Start: 2025-11-25Target: 60Updated: 2026-08-03